ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

DANNEL DOYLE FNP-C

2025 N 3RD ST SUITE 170

Phoenix | Arizona | 85004

(602) 462-1132

Incorrect Info?
Search this name in Dollars for Docs »

At A Glance: This Prescriber in 2012

Nurse Practitioner, Family

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,306Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 417

$350K Total Retail Price of All Prescriptions

Rank: 21 out of 417

252 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arizona
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 252 patients filled at least one prescription for a schedule two drug, compared to an average of 15%.

Schedule Three
Controlled Substances

20% of this provider’s 252 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 7,730 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arizona
LISINOPRIL 418 399 1 1
LEVOTHYROXINE SODIUM 395 385 2 2
RISPERIDONE 352 341 3 39
SIMVASTATIN 340 323 4 3
FUROSEMIDE 276 250 5 11
DONEPEZIL HCL 263 260 6 27
DIVALPROEX SODIUM 223 208 7 52
TRAZODONE HCL 220 215 8 22
HYDROCODONE-ACETAMINOPHEN 212 206 S3 9 4
CITALOPRAM HBR 211 201 10 16
OMEPRAZOLE 187 170 11 6
WARFARIN SODIUM 186 173 12 14
AMLODIPINE BESYLATE 166 155 13 7
MIRTAZAPINE 162 162 14 79
NAMENDA 134 132 15 47
QUETIAPINE FUMARATE 117 102 16 51
SERTRALINE HCL 112 110 17 40
PAROXETINE HCL 107 95 18 110
ATENOLOL 106 94 19 18
METOPROLOL TARTRATE 106 101 19 12
ISOSORBIDE MONONITRATE ER 102 102 21 67
ADVAIR DISKUS 100 100 22 59
HYDROCHLOROTHIAZIDE 98 87 23 13
TRAMADOL HCL 96 86 24 33
DIGOXIN 94 87 25 57
KLOR-CON M20 93 89 26 91
GABAPENTIN 89 85 27 9
LANTUS 84 84 28 21
RANITIDINE HCL 83 58 29 20
ALENDRONATE SODIUM 82 74 30 28
KLOR-CON M10 79 79 31 121
METFORMIN HCL 74 69 32 5
LEVETIRACETAM 70 52 33 105
CARVEDILOL 69 59 34 34
LACTULOSE 65 62 35 102
FAMOTIDINE 60 58 36 106
SPIRONOLACTONE 56 56 37 84
HYDRALAZINE HCL 55 55 38 96
FLUTICASONE PROPIONATE 55 49 38 35
FLUOXETINE HCL 53 32 40 60
CLONIDINE HCL 53 53 40 73
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.